Tags

Type your tag names separated by a space and hit enter

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Osteoporos Int. 2010 Jul; 21(7):1277-85.OI

Abstract

Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.

INTRODUCTION

To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.

METHODS

In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.

RESULTS

Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).

CONCLUSIONS

Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.

Authors+Show Affiliations

Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK. r.eastell@sheffield.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19802508

Citation

Eastell, R, et al. "Effect of Once-yearly Zoledronic Acid On the Spine and Hip as Measured By Quantitative Computed Tomography: Results of the HORIZON Pivotal Fracture Trial." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 21, no. 7, 2010, pp. 1277-85.
Eastell R, Lang T, Boonen S, et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2010;21(7):1277-85.
Eastell, R., Lang, T., Boonen, S., Cummings, S., Delmas, P. D., Cauley, J. A., Horowitz, Z., Kerzberg, E., Bianchi, G., Kendler, D., Leung, P., Man, Z., Mesenbrink, P., Eriksen, E. F., & Black, D. M. (2010). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 21(7), 1277-85. https://doi.org/10.1007/s00198-009-1077-9
Eastell R, et al. Effect of Once-yearly Zoledronic Acid On the Spine and Hip as Measured By Quantitative Computed Tomography: Results of the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2010;21(7):1277-85. PubMed PMID: 19802508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. AU - Eastell,R, AU - Lang,T, AU - Boonen,S, AU - Cummings,S, AU - Delmas,P D, AU - Cauley,J A, AU - Horowitz,Z, AU - Kerzberg,E, AU - Bianchi,G, AU - Kendler,D, AU - Leung,P, AU - Man,Z, AU - Mesenbrink,P, AU - Eriksen,E F, AU - Black,D M, AU - ,, Y1 - 2009/10/03/ PY - 2009/04/03/received PY - 2009/08/26/accepted PY - 2009/10/6/entrez PY - 2009/10/6/pubmed PY - 2011/4/19/medline SP - 1277 EP - 85 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 21 IS - 7 N2 - UNLABELLED: Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength. INTRODUCTION: To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength. METHODS: In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated. RESULTS: Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001). CONCLUSIONS: Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength. SN - 1433-2965 UR - https://www.unboundmedicine.com/medline/citation/19802508/Effect_of_once_yearly_zoledronic_acid_on_the_spine_and_hip_as_measured_by_quantitative_computed_tomography:_results_of_the_HORIZON_Pivotal_Fracture_Trial_ L2 - https://doi.org/10.1007/s00198-009-1077-9 DB - PRIME DP - Unbound Medicine ER -